BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 29, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Stimuvax: Phase III hold

FDA placed a clinical hold on Stimuvax due to a case of encephalitis observed in a multiple myeloma (MM) patient in a Phase II trial. Partner Merck KGaA temporarily suspended enrollment in all Stimuvax clinical trials, including three...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >